Posizioni attive di Keun Chan Park
Società | Posizione | Inizio | Fine |
---|---|---|---|
Theromics, Inc.
Theromics, Inc. Medical SpecialtiesHealth Technology Theromics, Inc. is a medical device technology company that is developing a next-generation thermal accelerant technology for soft tissue ablation procedures and combination therapy. The company is based in West Bridgewater, MA. The company's proprietary heatsync™ gel is based on a protein naturally found in the body and may increase cost-efficiencies and improve outcomes through more focused and patient-centric delivery. The company will first focus on tumor ablations and then expand into additional applications, including pain and abnormal uterine bleeding. Longer-term, Theromics plans to apply its thermal technology for use as an oncolytic intratumoral drug/immunotherapy delivery platform with the potential to enhance efficacy and improve safety profiles of currently approved medicines. The company was founded by Damian E. Dupuy, William Keun Chan Park. The CEO is Ron Murphy. | Direttore Tecnico/Scientifico/R&S | - | - |
Fondatore | - | - |
Storia della carriera di Keun Chan Park
Statistiche
Distribuzione geografica
Stati Uniti | 2 |
Posizioni
Chief Tech/Sci/R&D Officer | 1 |
Founder | 1 |
Settori
Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 1 |
---|---|
Theromics, Inc.
Theromics, Inc. Medical SpecialtiesHealth Technology Theromics, Inc. is a medical device technology company that is developing a next-generation thermal accelerant technology for soft tissue ablation procedures and combination therapy. The company is based in West Bridgewater, MA. The company's proprietary heatsync™ gel is based on a protein naturally found in the body and may increase cost-efficiencies and improve outcomes through more focused and patient-centric delivery. The company will first focus on tumor ablations and then expand into additional applications, including pain and abnormal uterine bleeding. Longer-term, Theromics plans to apply its thermal technology for use as an oncolytic intratumoral drug/immunotherapy delivery platform with the potential to enhance efficacy and improve safety profiles of currently approved medicines. The company was founded by Damian E. Dupuy, William Keun Chan Park. The CEO is Ron Murphy. | Health Technology |
- Borsa valori
- Insiders
- Keun Chan Park
- Esperienza